oveporexton

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

Takeda's narcolepsy programme gets back on track

Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.

Digital

pharmaphorum podcast Episode 232, Kate Eversole, Celine Parmentier, Emma Slade

On the future of AI in life sciences, with women at the helm

Dive into a conversation on women in AI, with: Kate Eversole, Pharma Brands; Celine Parmentier, Real Chemistry; and Emma Slade, Tangram Therapeutics.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks